Locations:
A rare opportunity to design for speed, care coordination, recovery and continuous monitoring
Multidisciplinary, proactive approach also improved discharge outcomes
Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26
Inflammatory protein eotaxin-1 may be a marker of future cognitive decline
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Therapists and physicians collaborate to get medically stable patients moving
Designed for digitization, distance health, discovery and more
Combining customized care, research capabilities and flexibility for the future
Using the EMR to identify subtle symptoms at triage
Leading investigators outline a new roadmap for clinical trials and observational research
The selective D1/D5 dopamine agonist provides symptom relief and improves daily function.
Advertisement
Advertisement
Search